IgG Subtyping Assay for Transplant Compatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current crossmatching techniques for organ and tissue transplantation are laborious and not always indicative of interactions between recipient antibodies and donor cells, making it difficult to quickly and accurately determine tissue compatibility and predict transplant rejection.
Innovation Solution
A method involving contacting donor leukocytes with recipient antibodies to assess binding for specific IgG subtypes (IgG1, IgG2, IgG3, and IgG4) using flow cytometry, allowing for a single assay to determine compatibility and predict graft rejection, with the option to distinguish between T and B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current crossmatching techniques are used to assess tissue compatibility, then tissue compatibility can be assessed, but the process is laborious and not always indicative of interactions between recipient antibodies and donor cells
Solution Approach 1:
The patent uses flow cytometry to create a quantitative copy of the antibody-antigen interaction data, measuring the binding between recipient antibodies and donor leukocytes with precise numerical values. This copying approach replaces subjective visual assessment with objective numerical measurements, improving accuracy while maintaining procedural feasibility
Solution Approach 2:
The patent replaces the mechanical/manual crossmatching procedures with flow cytometry technology, which uses optical detection and electronic data processing to assess antibody binding. This substitution automates the measurement process, reduces human labor, and provides more precise quantification of tissue compatibility
2Loss of time
If current crossmatching techniques are used, then tissue compatibility can be determined, but it is difficult to quickly and accurately predict transplant rejection
Solution Approach 1:
The patent enables continuous assessment of multiple antibody subtypes simultaneously through flow cytometry, allowing all necessary measurements to be performed in a single integrated assay. This continuous measurement approach eliminates the need for sequential testing, reducing time loss while maintaining high accuracy in rejection prediction
Solution Approach 2:
The patent combines the assessment of multiple IgG subclasses (IgG1, IgG2, IgG3, IgG4) into a single flow cytometry assay, merging what would traditionally require multiple separate tests. This consolidation reduces the time required for compatibility assessment while improving the accuracy of rejection prediction through comprehensive antibody profiling
3Reliability
If IgG subclass-specific antibodies are used in flow crossmatching, then complement fixation can be detected, but multiple labeled reagents are required
Solution Approach 1:
The patent employs a universal fluorophore-conjugated anti-human IgG Fc region antibody that can detect all IgG subclasses (IgG1, IgG2, IgG3, IgG4) through a single reagent. This universal detector binds to the Fc region of any IgG subclass, eliminating the need for multiple subclass-specific labeled reagents while maintaining the ability to predict complement fixation based on the presence of complement-fixing subclasses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a more accurate and efficient assessment of tissue compatibility, identifying potential graft rejection and increasing the number of successful transplants by distinguishing between complement-activating and non-complement-activating antibodies, thereby improving transplant outcomes.
Implementation Method 1
contacting leukocytes obtained from the donor of a potential transplant tissue with blood serum obtained from a proposed recipient of the transplant tissue... If the recipient's serum includes antibodies which bind specifically with antigens which appear on donor lymphocytes, such binding can be detected
Implementation Method 2
The lymphoctyes are then contacted with a labeled reagent capable of detecting recipient antibodies (e.g., a fluoresceinated antibody which binds to human antibodies... and thereafter rinsing non-bound labeled reagent from the lymphocytes. Binding of recipient antibodies with donor lymphocytes is detected by suspending the lymphocytes in a fluid and passing them through a flow cytometer capable of detecting the label of the labeled reagent. Detection of the label together with a lymphocyte by the flow cytometer (e.g., detection of fluorescence corresponding to fluorescein) indicates that one or more recipient antibodies recognized by the labeled reagent is bound to the lymphocyte
Data Source
AI summary
The disclosure relates to methods for assessing the suitability of a tissue obtained from a vertebrate (e.g., human) donor for grafting to a recipient, such as another vertebrate of the same species. The method involves contacting leukocytes obtained from the donor with serum from the recipient. Binding between recipient antibodies and the leukocytes is assessed, specifically focusing on the subtype(s) of IgG antibodies which bind with donor leukocytes. Detected binding between recipient antibodies of subtypes IgG1 and IgG3 indicates that the donor tissue is not suitable for grafting to the recipient. Detected binding between recipient antibodies of subtypes IgG2 and/or IgG4 indicates that the donor tissue can suitably be grafted to the recipient.